Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia Research Reports"
DOI: 10.1016/j.lrr.2018.01.002
Abstract: Rituximab (R) (Rituxan®, Roche, Basel Switzerland) is the first antiCD20 monoclonal antibody that has demonstrated efficacy in patients with various lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic… read more here.
Keywords: lymphoma; given patients; patients indications; indications cd20 ... See more keywords